CAMP

CAMP4 Therapeutics Corp

3.82

Nov 06 • 3:14 PM ET +0.10 (2.69%)

Healthcare Biotechnology USA Micro NASD

Nov 05, 9:45 PMCAMP4 Therapeutics Corp reports fiscal Q3 2026 results with non-GAAP EPS $-0.37 (+33% YoY) and revenue $1.9M (+139% YoY), misses EPS but beats revenue estimates

Peers: STOK IONS WVE KRRO ADRX PRQR ARWR SLN RARE BNTC

| Held by: VTI IWM VXF IWO VTWO IWC BUSM GSSC VTWG RSSL

Scroll to Statements

Index	RUT
Market Cap	239.72M
Enterprise Value	154.96M
Income	-107.24M
Sales	4.22M
Book/sh	-0.01
Cash/sh	1.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	48
IPO	Oct 11, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	56.80
P/B	-
P/C	2.75
P/FCF	-
EV/EBITDA	-
EV/Sales	36.72
Quick Ratio	4.70
Current Ratio	4.70
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-2.23
EPS next Y	-0.73
EPS next Q	-0.17
EPS this Y	51.15%
EPS next Y	43.73%
EPS next 5Y	34.92%
EPS past 3/5Y	-5.31% -
Sales past 3/5Y	- -
EPS Y/Y TTM	13.40%
Sales Y/Y TTM	40.21%
EPS Q/Q	7.30%
Sales Q/Q	18.84%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-90.92% 10.62%

Insider Own	50.81%
Insider Trans	-1.69%
Inst Own	53.32%
Inst Trans	1.10%
ROA	-148.23%
ROE	-545.85%
ROIC	-12228.51%
Gross Margin	57.12%
Oper. Margin	-1242.50%
Profit Margin	-2543.74%
SMA20	8.10%
SMA50	-0.46%
SMA200	-8.82%
Trades

Shs Outstand	51.93M
Shs Float	30.87M
Short Float	11.18%
Short Ratio	13.21
Short Interest	3.45M
52W High	7.75 -50.71%
52W Low	2.90 31.72%
Volatility	8.09% 8.17%
ATR (14)	0.30
RSI (14)	54.06
Beta	0.36
Rel Volume	0.27
Avg Volume	261.18K
Volume	63,313

Perf Week	-3.54%
Perf Month	3.24%
Perf Quarter	-9.48%
Perf Half Y	-14.35%
Perf YTD	-37.68%
Perf Year	-14.16%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	9.90
Prev Close	3.72
Price	3.82
Change %	2.69%

Consensus

Strong Buy

Avg. Price Target

$9.90

Implied Upside

+159.2%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 23, 2026	Initiated	RRaymond James	Strong Buy	$10	+161.8%
Oct 15, 2026	Initiated	NNeedham	Buy	$8	+109.4%
Oct 05, 2026	Initiated	OOppenheimer	Outperform	$15	+292.7%
Jun 16, 2026	Upgrade	JJP Morgan	Neutral → Overweight	$9	+135.6%
Jun 10, 2026	Initiated	CChardan Capital Markets	Buy	$6.50	+70.2%
Apr 14, 2026	Initiated	RRodman & Renshaw	Buy	$7	+83.2%
Oct 02, 2025	Initiated	CCantor Fitzgerald	Overweight	$7	+83.2%
Sep 16, 2025	Downgrade	JJP Morgan	Overweight → Neutral
May 27, 2025	Initiated	WWedbush	Outperform	$8	+109.4%
Nov 05, 2024	Initiated	WWilliam Blair	Outperform
Nov 05, 2024	Initiated	PPiper Sandler	Overweight	$18	+371.2%
Nov 05, 2024	Initiated	JJP Morgan	Overweight	$23	+502.1%

Nov-05-26 04:05PM	CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-27-26 08:00AM	CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union (GlobeNewswire) +13.71%
Oct-14-26 08:00AM	CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference (GlobeNewswire)
Sep-10-26 07:33AM	CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder (GlobeNewswire)
Sep-08-26 04:05PM	CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 (GlobeNewswire)
04:05PM	Loading…
Sep-01-26 04:05PM	CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-26 04:05PM	CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +20.89%
Aug-04-26 07:00AM	CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement (GlobeNewswire)
Jul-27-26 07:00AM	CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder (GlobeNewswire) +8.23%
Jul-17-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.51%
Jun-19-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-21-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-26 07:00AM	CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder (GlobeNewswire)
May-07-26 04:05PM	CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +6.90%
Apr-28-26 08:00AM	CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation (GlobeNewswire)
04:05PM	Loading…
Apr-17-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-24-26 07:00AM	CAMP4 Appoints Michael MacLean to its Board of Directors (GlobeNewswire)
Mar-06-26 04:05PM	CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.50% +49.40%
Mar-05-26 04:05PM	CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights (GlobeNewswire) +12.50%
Feb-20-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-16-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.00%
Jan-13-26 12:00PM	CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why (Zacks)
Jan-06-26 08:00AM	CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-19-25 06:01AM	Novo files for CagriSema approval; Merck and Pfizers trial win (BioPharma Dive)
Dec-18-25 07:10AM	CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock (GlobeNewswire) -12.90%
07:00AM	CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries (GlobeNewswire)
Dec-12-25 04:05PM	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.99%
Nov-14-25 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 04:05PM	CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.97%
02:09PM	Loading…
Oct-14-25 02:09PM	3 Healthcare Companies Insiders Are Buying (MarketBeat) -6.63%
Oct-01-25 08:00AM	CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 (GlobeNewswire)
Sep-25-25 12:00PM	CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know (Zacks) +7.53%
Sep-17-25 09:40AM	Apple initiated, Hershey upgraded: Wall Streets top analyst calls (TipRanks) -6.50%
Sep-16-25 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
Sep-10-25 07:00AM	CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders (GlobeNewswire) +40.20%
Aug-14-25 04:05PM	CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.16% +7.74%
Jun-30-25 08:00AM	Sequans Appoints Jason W. Cohenour to Board of Directors (Newsfile)
May-16-25 06:00AM	CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) +9.52%
May-13-25 04:05PM	CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) -7.92%
Apr-28-25 04:30PM	CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) -10.00% -5.15%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-27-25 04:05PM	CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -10.16%
Mar-18-25 08:00AM	CAMP4 Appoints Multiple Industry Veterans to its Board of Directors (GlobeNewswire)
Mar-04-25 05:24AM	CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 (Insider Monkey) -5.27%
Feb-06-25 08:00AM	CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.95%
Jan-13-25 08:00AM	CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 04:05PM	CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire) -8.08%
Dec-02-24 08:00AM	CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +5.85%
Nov-21-24 04:05PM	CAMP4 Reports Third Quarter 2024 Financial Results (GlobeNewswire) +8.44% -6.40%
Oct-10-24 07:07PM	CAMP4 Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gold Kelly	Chief Financial Officer	Aug 31 '26	Buy	3.96	10,000	39,600	10,000	Sep 02 07:50 PM
Schwab Andrew J.	Director	Aug 27 '26	Sale	4.04	400,000	1,616,000	2,033,270	Aug 31 05:05 PM
Schwab Andrew J.	Director	Aug 24 '26	Sale	4.50	10	45	2,433,270	Aug 26 04:57 PM
Schwab Andrew J.	Director	Aug 20 '26	Sale	4.54	114,700	520,738	2,465,298	Aug 21 04:59 PM
Schwab Andrew J.	Director	Aug 19 '26	Sale	4.76	45,147	214,900	2,579,998	Aug 21 04:59 PM
Schwab Andrew J.	Director	Aug 21 '26	Sale	4.50	32,018	144,081	2,433,280	Aug 21 04:59 PM
Tardiff Daniel	Chief Scientific Officer	Aug 19 '26	Sale	4.76	1,738	8,273	0	Aug 19 08:46 PM
Daniel Tardiff	affiliate	Aug 19 '26	Proposed Sale	4.76	1,738	8,276		Aug 19 10:23 AM
Young Richard A	Director	Aug 03 '26	Buy	1.65	16,378	27,024	186,388	Aug 05 05:09 PM
Maricich Yuri	Chief Medical Officer	Aug 03 '26	Buy	1.65	6,551	10,809	12,611	Aug 05 05:08 PM
Gold Kelly	Chief Financial Officer	Aug 03 '26	Buy	1.65	6,551	10,809	74,428	Aug 05 05:08 PM
Mandel-Brehm Josh	Chief Executive Officer	Aug 03 '26	Buy	1.65	6,551	10,809	284,968	Aug 05 05:07 PM

CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CEOMr. Joshua Mandel-Brehm

Founder & Independent DirectorDr. Richard A. Young Ph.D.

Chief Financial OfficerMs. Kelly Gold

M.D.Dr. Yuri Maricich M.B.A.

Founder & Chairman of Scientific Advisory BoardDr. Leonard I. Zon M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAMP

CAMP4 Therapeutics Corp

Upgrade your Finviz experience